Overview
Proximal Xq28 duplication syndrome (also known as Xq28 duplication syndrome or int22h1/int22h2-mediated Xq28 duplication syndrome) is a rare X-linked chromosomal disorder caused by a recurrent duplication in the proximal portion of the Xq28 region of the X chromosome. This duplication typically encompasses several genes, and the clinical presentation predominantly affects males, while carrier females are usually asymptomatic or mildly affected. The condition primarily impacts the neurological system, with affected individuals commonly presenting with intellectual disability ranging from mild to severe, developmental delay (particularly speech and language delay), and behavioral abnormalities. Recurrent infections, especially respiratory infections, are frequently observed and are thought to be related to immune dysregulation. Key clinical features include hypotonia (low muscle tone) in infancy, seizures or epilepsy, feeding difficulties in early life, and distinctive facial features that may include a long face, prominent forehead, and midface hypoplasia. Growth abnormalities and gastrointestinal problems such as gastroesophageal reflux and constipation may also be present. Some patients develop spasticity in the lower limbs over time. The severity of symptoms can vary considerably among affected individuals, even within the same family. There is currently no cure or specific targeted therapy for proximal Xq28 duplication syndrome. Management is supportive and symptomatic, involving a multidisciplinary team approach. This may include physical therapy, occupational therapy, speech therapy, antiepileptic medications for seizure control, and proactive management of recurrent infections. Early intervention programs and individualized educational support are important components of care. Genetic counseling is recommended for affected families to understand recurrence risks and carrier status.
Clinical phenotype terms— hover any for plain English:
X-linked recessive
Carried on the X chromosome; typically affects males more than females
Infantile
Begins in infancy, roughly 1 month to 2 years old
FDA & Trial Timeline
1 eventHuidaGene Therapeutics Co., Ltd. — NA
Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
Treatments
No FDA-approved treatments are currently listed for Proximal Xq28 duplication syndrome.
1 clinical trialare actively recruiting — trials can provide access to cutting-edge therapies.
View clinical trials →Specialists
View all specialists →No specialists are currently listed for Proximal Xq28 duplication syndrome.
Treatment Centers
8 centersPeking University First Hospital
📍 Beijing, Beijing Municipality
Stanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🏥 NORDBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
Travel Grants
No travel grants are currently matched to Proximal Xq28 duplication syndrome.
Community
No community posts yet. Be the first to share your experience with Proximal Xq28 duplication syndrome.
Start the conversation →Latest news about Proximal Xq28 duplication syndrome
Disease timeline:
New trial: A First-in-Human Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of a Novel CRISPR
Phase NA trial recruiting. HG204
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Proximal Xq28 duplication syndrome
What is Proximal Xq28 duplication syndrome?
Proximal Xq28 duplication syndrome (also known as Xq28 duplication syndrome or int22h1/int22h2-mediated Xq28 duplication syndrome) is a rare X-linked chromosomal disorder caused by a recurrent duplication in the proximal portion of the Xq28 region of the X chromosome. This duplication typically encompasses several genes, and the clinical presentation predominantly affects males, while carrier females are usually asymptomatic or mildly affected. The condition primarily impacts the neurological system, with affected individuals commonly presenting with intellectual disability ranging from mild t
How is Proximal Xq28 duplication syndrome inherited?
Proximal Xq28 duplication syndrome follows a x-linked recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does Proximal Xq28 duplication syndrome typically begin?
Typical onset of Proximal Xq28 duplication syndrome is infantile. Age of onset can vary across affected individuals.
Are there clinical trials for Proximal Xq28 duplication syndrome?
Yes — 1 recruiting clinical trial is currently listed for Proximal Xq28 duplication syndrome on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.